Summary:
DeNovo Biopharma DB104-01:
- A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment Resistant Depression
- Age 18-70
- Inclusion Criteria: Patient has tried 2 Antidepressant medications of a different class (SSRI or SNRI) in the past 5 years.
- Must actively be depressed.
- 14 Weeks, 9 visits
- Compensation: Up to $157 per visit
Janssen 67953964MDD3001:
- Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD). Open-Label extension study available upon completion.
- Age 18-74
- Must be currently taking an Anti-depressant medication that has not been working well enough.
- Must actively be depressed.
- 13 weeks, 9 visits
- Compensation: $100 per visit and up to $150 for travel per visit.
Criteria:DeNovo Biopharma DB104-01:
- A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment Resistant Depression
- Age 18-70
- Inclusion Criteria: Patient has tried 2 Antidepressant medications of a different class (SSRI or SNRI) in the past 5 years.
- Must actively be depressed.
Janssen 67953964MDD3001:
- Age 18-74
- Must be currently taking an Anti-depressant medication that has not been working well enough.
- Must actively be depressed.
Qualified Participants May Receive:
DeNovo Biopharma DB104-01:
- 14 Weeks, 9 visits
- Compensation: Up to $157 per visit
- Study related care at no cost. No Insurance required.
Janssen 67953964MDD3001:
- 13 weeks, 9 visits
- Compensation: $100 per visit and up to $150 for travel per visit.
- Study related care at no cost. No Insurance required.